Nuclear Medicine: Page 405

ProstaScint being tested as IMRT guide
By AuntMinnie.com staff writers
Radiopharmaceutical firm Cytogen said today that a new phase I/II clinical study will be evaluating the utility of its ProstaScint prostate cancer agent in helping to guide radioimmunoguided intensity modulated radiation therapy (IMRT) procedures.
June 5, 2002
Cytogen raises $5 million
By AuntMinnie.com staff writers
Radiopharmaceutical firm Cytogen has completed a private offering of common stock to the State of Wisconsin Investment Board.
June 4, 2002
Frost & Sullivan to offer U.S. radiopharmaceutical market analysis
By AuntMinnie.com staff writers
Market research firm Frost & Sullivan will hold a conference call at 3:00 p.m. (EDT) on June 5, 2002 to provide an overview of the U.S. radiopharmaceutical market.
May 30, 2002
Digirad reports record 2001, Q1
By AuntMinnie.com staff writers
Solid-state gamma camera developer Digirad reported record 2001 revenues of $32 million, up from $7.1 million in 2000. In addition, the firm said it booked 2002 first-quarter revenue of $9.1 million, up 42% from the $6.4 million recorded in the first quarter of 2001.
May 30, 2002
Cytogen brings BrachySeed Pd-103 to U.S.
By AuntMinnie.com staff writers
Pharmaceutical firm Cytogen and radiopharmaceutical manufacturer DraxImage have launched BrachySeed Pd-103 in the U.S.
May 29, 2002
Cytogen reveals 2002 forecast
By AuntMinnie.com staff writers
Radiopharmaceutical firm Cytogen expects total revenues in 2002 of $12.5 million to $14.5 million, representing 7% to 24% growth over 2001.
May 29, 2002
Amersham inks supply deal with Novation
By AuntMinnie.com staff writers
Amersham Health has signed a sole-source agreement to supply group purchasing organization Novation with its brachytherapy products.
May 28, 2002
PET, SPECT confirm: In Parkinson's, dopamine agonists work better than levodopa
By Edward Susman
Two long-term imaging studies are providing more evidence that dopamine agonists are superior to levodopa for the initial treatment of Parkinson's disease patients. One group of researchers looked at the motor function of these patients, while another other group investigated the drugs' effects in younger patients.
May 19, 2002
Positron trims loss, ships scanner in Q1
By AuntMinnie.com staff writers
PET manufacturer Positron reported first-quarter revenues of $1.5 million, more than double the $493,000 reported in the first quarter of 2001.
May 16, 2002
Immunomedics signs South American distributor
By AuntMinnie.com staff writers
Pharmaceutical firm Immunomedics has signed a marketing and distribution agreement with Teva-Tuteur of Buenos Aires, Argentina.
May 16, 2002
Draxis Health turns in record Q1
By AuntMinnie.com staff writers
Canadian radiopharmaceutical manufacturer Draxis Health reported record revenues of $10 million (U.S.) in the first quarter of 2002, up 18% from the $8.4 million booked in the first quarter last year.
May 15, 2002
FDG-PET results keep colorectal cancer patients out of the OR
By Shalmali Pal
With a relapse rate as high as 40%, colorectal cancer patients clearly need better preoperative assessment. Australian researchers investigated whether FDG-PET could be the modality to pick up where conventional imaging, and CT in particular, leaves off.
May 6, 2002
2002 05 06 11 10 31 706
Previous Page
Page 405 of 439
Next Page